The current findings suggested that WFS1 and EHHADH exerted their oncogenic effects by activating immune checkpoints, indicating that their expression levels may serve as biomarkers for predicting the efficacy of ICI in HCC patients, which should be further explored in the future. The gene discussed is EHHADH; the disease is hepatocellular carcinoma.